Table 4.
Univariate and multivariate analysis of prognostic factors for OS
| Variable | Modality | Reference | Univariate analysis | Multivariate analysis | ||||
|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |||
| Age | Continuous variable | 1.05 | 1.04-1.06 | <.001 | 1.02 | 1.01-1.03 | <.001 | |
| ECOG (0-1) | Yes | No | 0.23 | 0.17-0.30 | <.001 | 0.44 | 0.29-0.66 | <.001 |
| Sex | Female | Male | 0.86 | 0.64-1.16 | .326 | |||
| Localization | Disseminated with or without cutaneous localization | Cutaneous isolated | 1.57 | 1.17-2.11 | .003 | 2.31 | 1.65-3.23 | <.001 |
| Disseminated with cutaneous localization | 2.09 | 1.30-3.35 | .002 | 5.37 | 3.15-9. | <.001 | ||
| Extranodal disease | 1.47 | 0.87-2.51 | .154 | 4.68 | 2.61-8.40 | <.001 | ||
| Abnormal karyotype | Yes | No | 0.78 | 0.47-1.32 | .360 | |||
| CK | 1.02 | 0.59-1.77 | .938 | |||||
| MK | 0.71 | 0.33-1.50 | .362 | |||||
| Type of treatment | AL-type treatment | NHL-type treatment | 0.71 | 0.51-0.99 | .047 | 0.88 | 0.59-1.32 | .547 |
| AL- or NHL-type treatment + allo-HSCT | 0.17 | 0.10-0.30 | <.001 | 0.21 | 0.12-0.39 | <.001 | ||
| AL- or NHL-type treatment + auto-HSCT | 0.20 | 0.09-0.046 | <.001 | 0.24 | 0.10-0.59 | .002 | ||
| Radiotherapy | 0.74 | 0.45-1.22 | .242 | 1.32 | 0.74-2.35 | .353 | ||
| Palliative | 2.96 | 2.10-4.16 | <.001 | 2.23 | 1.48-3.34 | <.001 | ||
| Immunophenotype | CD4+ CD56+ CD123+ TCL1+ BDCA2+ | No | 1.90 | 1.15-3.13 | .013 | |||
| TdT+ | No | 0.65 | 0.46-0.93 | .019 | ||||
| CD34+ and/or CD117+ | No | 1.19 | 0.65-2.17 | .573 | ||||
| BCL2+ | No | 2.75 | 0.55-13.73 | .218 | ||||
| Country | Austria | France | 0.59 | 0.37-0.93 | .024 | 0.67 | 0.42-1.07 | .092 |
| Italy | 0.92 | 0.64-1.34 | .676 | 0.94 | 0.62-1.42 | .752 | ||
| Japan | 0.58 | 0.41-0.83 | .002 | 0.66 | 0.45-0.97 | .032 | ||
| United States | 0.63 | 0.43-0.92 | .018 | 0.62 | 0.40-0.97 | .035 | ||